Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Vertex Pharmaceuticals, best known for its breakthrough cystic fibrosis (CF) treatments, is to become one of the first partners of CRISPR Therapeutics, a leader in new gene-editing technology.

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

In a report released today, Gena Wang from Barclays maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report), with a price ...

Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday a reimbursement agreement with England’s National Health Service (NHS) ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biohaven Ltd. (BHVN – Research Report), ...

CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...